Panel releases best practices in cost-effectiveness analysis
By Lauren Neves | October 3, 2016
Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the...
Read More
Who gets a seat at ICER’s table? Hint: It’s not patients
By Holly Campbell | September 19, 2016
As we continue the move toward a value-driven health care system, efforts to develop tools supporting patient decision-making will play a central role. These tools, including emerging value...
Read More
ICER puts hard-fought progress in non-small cell lung cancer treatment at risk
By Holly Campbell | September 1, 2016
Lung cancer is the leading cause of cancer death among men and women in the United States, and each year, tens of thousands of Americans are diagnosed with the most common form, non-small cell...
Read More
What they are saying about ICER’s scoping document for non-small cell lung cancer
By Holly Campbell | July 11, 2016
The Institute for Clinical and Economic Review (ICER) has set its sights on a new target: life-saving treatments for advanced non-small cell lung cancer (NSCLC). ICER’s latest draft scoping...
Read More
ICER framework threatens to halt continued progress against multiple myeloma
By Holly Campbell | May 26, 2016
Progress in the fight against multiple myeloma, a cancer of the blood and bone marrow, has been nothing short of remarkable. Just a decade ago, patients diagnosed faced a poor prognosis and...
Read More
New academic initiative aims to inform approaches to value assessment frameworks
By Holly Campbell | May 13, 2016
As the U. S. health care market continues to shift toward a system that prioritizes and rewards value, there is increasing attention on the development and use of value assessment frameworks. When...
Read More
ICYMI - The Economists’ Voice: Are biopharmaceutical budget caps good public policy?
By Holly Campbell | May 6, 2016
In case you missed it, a recent article in The Economists’ Voice examines how assessing the value of medicines using budget caps would impede patient access and chill biopharmaceutical innovation....
Read More
How to get value assessment frameworks right
By Holly Campbell | April 1, 2016
As the U.S. health care market evolves toward a system that better recognizes and rewards value, we face a pressing need to develop tools and solutions to empower informed patient-physician...
Read More
A shared commitment to value
By Randy Burkholder | November 9, 2015
Last week, the New England Journal of Medicine published a perspective from PhRMA’s Dr. Bill Chin alongside a counterpoint by Dr. Peter Bach, and I was struck by the extent to which both pieces...
Read More
Value at the crossroads, part II
By Randy Burkholder | September 8, 2015
Value assessment in health care continues to generate considerable interest, as reflected in the wide range of comments sent to the American Society of Clinical Oncology (ASCO) on their Value...
Read More
Medicare Monday (100)
340B Spotlight (45)
Cost & Consequence (0)
